InterCure Completes Botanico Acquisition, Initiates Strategic Review for U.S. Medical Cannabis Market Entry
Summary
InterCure completed the initial closing of its Botanico acquisition, issuing approximately 2.47 million ordinary shares. This deal, also noted in a 6-K filed today, provides exclusive access to U.S. cannabis genetics, premium brands, and AI-driven technologies, significantly expanding the company's international platform. Concurrently, InterCure initiated a strategic review of U.S. medical cannabis opportunities, capitalizing on the recent federal rescheduling. This move positions the company for potential entry into a major new market, representing a significant growth opportunity.
At the time of this announcement, INCR was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50M. The 52-week trading range was $0.68 to $1.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.